Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis, spreads via aerosols and the first encounter with the immune system is with the pulmonary resident immune cells. The role of epigenetic regulations through DNA methylation in the immune cells is emerging. We have previously shown that capacity to kill M. tuberculosis is reflected in the DNA methylome. The aim of this study was to investigate epigenetic modifications in the pulmonary immune cells in a cohort of medical students with a previously documented increased risk of TB exposure, longitudinally. Sputum samples containing alveolar macrophages (AMs) and T cells were collected before and after study subjects worked in hospital departments with a high-risk of TB exposure. DNA methylome analysis revealed that a unique DNA methylation profile was present already at inclusion in subjects who developed latent TB during the study. The profile was both reflected in different overall DNA methylation distribution as well as more profound alterations in the methylation status of a unique set of CpG-sites. Over-representation analysis of the DMGs showed enrichment in pathways related to metabolic reprograming of macrophages and T cell migration and IFN-γ production. In conclusion, we identified a unique DNA methylation signature in individuals, while still IGRA-negative and who later developed latent TB. Epigenetic regulation was found in pathways that have previously been reported to be important in TB. Together the study suggests that DNA methylation status of pulmonary immune cells can predict IGRA conversion.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank the Bioinformatics and Expression Analysis core facility (BEA) at Karolinska Institute that preformed the sequencing analysis. We thank the Swedish National Infrastructure for Computing (SNIC) at National Supercomputing Centre (NSC), Linkoping University for the computing systems enabling the data handling, partially funded by the Swedish Research Council through grant agreement no. 2018-05973. The work was supported by grants from the Swedish Research Council (Vetenskapsradet) no. 2018-05973 and no. 2018- 04246 and the Consejo Nacional de Ciencia, Tecnologia e Innovacion Tecnologica CONCYTEC and Cienciactiva no. 106-2018-FONDECYT. J.D is a postdoctoral fellow supported through the Medical Infection and Inflammation Center (MIIC) at Linkoping University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from Universidad Peruana Cayetano Heredia (UPCH) Institutional Review Board no. 103793.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets will be made available at the final publication.
